Table 1 Comparison of cisplatin and lobaplatin
Category | Cisplatin | Lobaplatin |
|---|---|---|
Product generation | First generation | Third generation |
Chemical structure |
|
|
Anti-tumor mechanism | Forms DNA-drug adducts, resulting in DNA damage and cell apoptosis | |
Half-life period | Over 24 h (total platinum) [33], mainly metabolized through the kidney | 131 ± 15 min (free platinum) and 6.8 ± 4.3 days (total platinum) [19], mainly metabolized through the kidney |
Anti-tumor spectrum | Ovarian, testicular, bladder, colorectal, lung, head and neck cancer | Metastatic breast cancer, chronic myelogenous leukemia, and small cell lung cancer |
Side effects | Nephrotoxicity, cumulative peripheral sensory neuropathy, ototoxicity, nausea and vomiting | Thrombocytopenia |
Additional medication | Hydration for high dose | No |
Solvent | Normal saline or glucose | Glucose |
Drug resistance | Easy to produce | Rare and no cross-resistance with cisplatin |
Expense per cycle for platinum drugs | ¥160.0-200.0 ($23.8-29.8) | ¥2800.0-3400.0 ($417.9-507.5) |
